Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may help solve early puberty puzzle in girls

NCT ID NCT07359092

Knowledge-focused Sponsor: Kayseri City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 143 girls to see if two natural chemicals in the blood, spexin and phoenixin-20, can help doctors tell the difference between true central precocious puberty and a harmless condition called premature thelarche. Researchers measured these chemicals in girls with early breast development and in healthy controls. The goal is to find a simple blood test that could guide diagnosis and avoid unnecessary treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to a simple blood test to help doctors tell the difference between central precocious puberty and harmless early breast development.
What could go wrong
This is a small, completed observational study, not a treatment trial. The findings need to be confirmed in larger, more diverse groups before any diagnostic test becomes available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

143 people

The number who actually took part.

Started

Dec 2024

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Girls younger than 8 years who presented for evaluation of early pubertal signs between December 2024 and December 2025. Participants were classified into two groups: CPP and PT; according to LH-RH stimulation test peak LH levels. And a third group was included (totally three groups) for age matched healthy controls.

Ages

4 to 8 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex * Age younger than 8 years, * Presentation for evaluation of early pubertal signs (breast development) * Classification into one of the following groups: central precocious puberty, premature thelarche, or healthy control Exclusion Criteria: * Presence of peripheral precocious puberty, * Known chronic systemic disease, * Use of medications affecting the hypothalamic-pituitary-gonadal axis, * Known genetic syndromes of congenital endocrine disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central precocious puberty (CPP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central precocious puberty precocious puberty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central precocious puberty (CPP) Hypothalamic-pituitary-ovarian axis dysfunction (disorder) Puberty Puberty disorders

Contacts and locations

Locations

  • Kayseri City Hospital

    Kayseri, 38080, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.